Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?
Price, A.J.; Obeid, D.
Annals of the Royal College of Surgeons of England 77(5): 395
1995
ISSN/ISBN: 0035-8843 PMID: 7486773 Document Number: 443444
Document emailed within 1 workday
Related Documents
Haas, S.; Stemberger, A.; Fritsche, H.M.; Welzel, D.; Wolf, H.; Lechner, F.; Blümel, G. 1987: Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine Arzneimittel-Forschung 37(7): 839-843Levine, M.N.; Planes, A.; Hirsh, J.; Goodyear, M.; Vochelle, N.; Gent, M. 1989: The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement Thrombosis and Haemostasis 62(3): 940-944
Heit, J.A.; Berkowitz, S.D.; Bona, R.; Cabanas, V.; Corson, J.D.; Elliott, C.G.; Lyons, R. 1997: Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group Thrombosis and Haemostasis 77(1): 32-38
Lee, L.H.; Liauw, P.C.; Ng, A.S. 1996: Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valve replacement Thrombosis and Haemostasis 76(4): 628-630
Neri Serneri, G.G. 1993: Heparin, low-molecular-weight heparin and their clinical use Annali Italiani di Medicina Interna: Organo Ufficiale Della Societa Italiana di Medicina Interna 8(2): 69-72
Yang, Z.; Liu, X.; Dai, S.; Liu, K.; Zhang, Y.; Sun, J.; Yin, X. 2010: Effectiveness of low molecular weight heparin for prevention of deep vein thrombosis after total hip arthroplasty Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 24(9): 1058-1061
Bartel, D.L.; Bicknell, V.L.; Wright, T.M. 1986: The effect of conformity, thickness, and material on stresses in ultra-high molecular weight components for total joint replacement Journal of Bone and Joint Surgery. American Volume 68(7): 1041-1051
Koppenhagen, K.; Tröster, E.; Matthes, M.; Häring, R. 1990: Prevention of thrombosis with low molecular weight heparin as the only substance and/or with DHE: results of clinical studies Langenbecks Archiv für Chirurgie. Supplement Ii Verhandlungen der Deutschen Gesellschaft für Chirurgie. Deutsche Gesellschaft für Chirurgie. Kongress 1990: 1163-1166
Schwarz, B.; Mittelmeier, H. 1988: Initial clinical experiences with low molecular weight heparin in the prevention of thrombosis in orthopedic surgery Aktuelle Traumatologie 18(5): 226-232
Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264
Uzan, A.; Marin, J.; Mardiguian, J.; Trillou, M.; Kiosseff, T.; Rougeot, C. 1987: Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S Annales Pharmaceutiques Francaises 45(6): 429-437
Bannon, P.G.; Kim, M.J.; Dean, R.T.; Dawes, J. 1995: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin Thrombosis and Haemostasis 73(4): 706-712
Eriksson, E.; Wollter, I.M.; Christenson, B.; Stigendal, L.; Risberg, B. 1988: Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin Thrombosis and Haemostasis 59(2): 284-288
Párama, J.A.; Llorens, R.; Sáenz de Buruaga, J.; Rocha, E. 1994: Low-molecular-weight heparin in a patient with heparin-induced thrombocytopenia and a cardiopulmonary bypass Medicina Clinica 102(16): 637-638
Huisse, M.G.; Huet, Y.; Zygelman, M.; Guillin, M.C. 1983: Thrombopenia induced by standard heparin. Therapeutic attempt using a low molecular weight heparin Presse Medicale 12(10): 643
Nakagawa, M. 1993: Heparin, low molecular weight heparin, heparinoid, and antithrombin IIi therapy of disseminated intravascular coagulation Nihon Rinsho. Japanese Journal of Clinical Medicine 51(1): 87-92
Kaiser, B.; Hauptmann, J.; Markwardt, F. 1988: Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative Folia Haematologica 115(1-2): 119-125
Bârzu, T.; Molho, P.; Tobelem, G.; Petitou, M.; Caen, J.P. 1984: Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture Nouvelle Revue Francaise d'Hematologie 26(4): 243-247
Morita, Y.; Makino, H.; Ota, K.; Wada, J.; Shikata, K.; Kashihara, N.; Ikeda, S.; Ogura, T.; Ota, Z. 1994: Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis Nihon Jinzo Gakkai Shi 36(7): 832-838
Chigot, P.; De Gennes, C.; Samama, M.M. 1996: Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin Journal des Maladies Vasculaires 21(3): 121-125